Sunesis Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Sunesis Pharmaceuticals Inc.
Eventide Healthcare & Life Sciences Fund
2,265,455
6.27%
0
0.71%
06/29/2018
Vanguard Total Stock Market Index Fund
672,732
1.86%
0
0%
07/31/2018
Rhenman & Partners Fund - Healthcare Equity L/S
450,100
1.25%
450,100
0.07%
12/31/2017
Vanguard Extended Market Index Fund
363,659
1.01%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
110,982
0.31%
0
0%
07/31/2018
iShares Micro Cap ETF
88,034
0.24%
0
0.02%
09/06/2018
FCP OP Medical BioHe@lth-Trends
60,000
0.17%
60,000
0.08%
11/30/2017
Vanguard Institutional Total Stock Market Index Fund
45,662
0.13%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
29,991
0.08%
0
0%
07/31/2018
Vanguard Balanced Index Fund
22,341
0.06%
0
0%
07/31/2018
| Address |
395 Oyster Point Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.sunesis.com |
| Updated |
07/08/2019 |
| Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. |
